The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE
Open Access
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (7) , 1070-1077
Abstract
Objectives Genetic variants in the transcription factor STAT4 are associated with increased susceptibility to systemic lupus erythematosus (SLE) and a more severe disease phenotype. This study aimed to clarify how the SLE-associated intronic STAT4 risk allele rs7574865[T] affects the function of immune cells in SLE. Methods Peripheral blood mononuclear cells (PBMCs) were isolated from 52 genotyped patients with SLE. Phosphorylation of STAT4 (pSTAT4) and STAT1 (pSTAT1) in response to interferon (IFN)-α, IFN-γ or interleukin (IL)-12, total levels of STAT4, STAT1 and T-bet, and frequency of IFN-γ+ cells on IL-12 stimulation were determined by flow cytometry in subsets of immune cells before and after preactivation of cells with phytohaemagglutinin (PHA) and IL-2. Cellular responses and phenotypes were correlated to STAT4 risk allele carriership. Janus kinase inhibitors (JAKi) selective for TYK2 (TYK2i) or JAK2 (JAK2i) were evaluated for inhibition of IL-12 or IFN-γ-induced activation of SLE PBMCs. Results In resting PBMCs, the STAT4 risk allele was neither associated with total levels of STAT4 or STAT1, nor cytokine-induced pSTAT4 or pSTAT1. Following PHA/IL-2 activation, CD8+ T cells from STAT4 risk allele carriers displayed increased levels of STAT4 resulting in increased pSTAT4 in response to IL-12 and IFN-α, and an augmented IL-12-induced IFN-γ production in CD8+ and CD4+ T cells. The TYK2i and the JAK2i efficiently blocked IL-12 and IFN-γ-induced activation of PBMCs from STAT4 risk patients, respectively. Conclusions T cells from patients with SLE carrying the STAT4 risk allele rs7574865[T] display an augmented response to IL-12 and IFN-α. This subset of patients may benefit from JAKi treatment.Keywords
Funding Information
- Swedish Society of Medicine and the Ingegerd Johansson donation
- Erik, Karin and Gösta Selanders Foundation
- Center for Innovative Medicine
- King Gustav V’s 80-year Foundation
- Vetenskapsrådet
- Swedish Rheumatism Association
- AstraZeneca Science for Life Laboratory research collaboration grant
- Norwegian Research Council
- Knut and Alice Wallenberg Foundation
This publication has 46 references indexed in Scilit:
- Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2Leukemia, 2011
- Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2010
- A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosusNature Genetics, 2009
- High‐density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groupsArthritis & Rheumatism, 2009
- Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritisClinical and Experimental Immunology, 2008
- A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5Human Molecular Genetics, 2008
- Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus ErythematosusPLOS Genetics, 2008
- STAT4and the Risk of Rheumatoid Arthritis and Systemic Lupus ErythematosusNew England Journal of Medicine, 2007
- Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4.Journal of Experimental Medicine, 1995
- Immune Interferon in the Circulation of Patients with Autoimmune DiseaseNew England Journal of Medicine, 1979